A controlled, evidence-based trial of paliperidone palmitate, a Long-acting injectable antipsychotic, in schizophrenia

Neuropsychopharmacology

Volumn 35, Issue 10, 2010, Pages 2072-2082

  Nasrallah, Henry A ^a   Gopal, Srihari ^b   Gassmann Mayer, Cristiana ^b   Quiroz, Jorge A ^b,d,e   Lim, Pilar ^b   Eerdekens, Mariëlle ^c   Yuen, Eric ^b   Hough, David ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

^d Johnson and Johnson   (United States)

^e Development and Exploratory Neuroscience   (United States)

Author keywords

antipsychotic; efficacy; injectable; long acting; paliperidone palmitate; schizophrenia

Indexed keywords

PALIPERIDONE; PLACEBO;

ADULT; AGITATION; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INCIDENCE; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; SWELLING; VISUAL ANALOG SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BODY MASS INDEX; BODY WEIGHT; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INJECTIONS; ISOXAZOLES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PALMITATES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77955716709     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.79     Document Type: Article

References (31)

1. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154: 672-676.
2. Bhanji NH, Chouinard G, Margolese HC (2004). A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 14: 87-92.
3. Cooper D, Moisan J, Gregoire JP (2007). Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 68: 818-825.
4. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P et al (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93: 117-130.
5. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH (2006). Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 144: 177-189.
6. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM et al (2010). Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Intl Clin Psychopharm (e-pub ahead of print 10 April 2010).
7. Guy W (1976). AIMS. In: Guy W (ed). ECDEU Assessment Manual for Psychopharmacology. Department of Health, Education, and Welfare: Rockville, MD. pp 534-537.
8. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M (2008). Paliperidone palmitate, an injectable antipsychotic, in prevention of symptom recurrence in patients with schizophrenia: a randomized,double-blind, placebo-controlled study. In Biol Psych. Society of Biological Psychiatry (SOBP), Washington, DC USA, pp 285S-286S.
9. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V et al (2009). Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33: 1022-1031.
10. Intralipid (2007). (prescribing information) Fresenius Kabi AB Uppsala, Sweden.
11. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P et al (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90: 147-161.
12. Kane JM, Leucht S, Carpenter D, Docherty JP (2003). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64(Suppl 12): 5-19.
13. Keith SJ, Kane JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 64: 1308-1315.
14. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y et al (2010). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Intl J Neuropsychopharm 13: 635-647.
15. Kramer M, Simpson G, Maciulis V, Kushner S, Vijapurkar U, Lim P et al (2007). Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharm 27: 6-14.
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
17. Love RC (2002). Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 59(22 Suppl 8): S10-S15.
18. Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K et al (2007). A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 22: 299-308.
19. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M et al (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62: 1363-1370.
20. Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A et al (2007). Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 40: 257-263.
21. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101: 323-329.
22. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M (2004). Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry 65: 531-536.
23. Nasrallah HA (2007). The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115: 260-267.
24. Nasrallah H, Morosini P, Gagnon DD (2008). Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia. Psychiatry Res 161: 213-224.
25. Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D et al (2009). Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 25: 325-338.
26. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212: 11-19.
27. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA et al (2006). Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163: 611-622.
28. Tandon R (2002). Safety and tolerability: how do newer generation 'atypical' antipsychotics compare? Psychiatr Q 73: 297-311.
29. Tandon R, Jibson MD (2002). Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 14: 123-129.
30. Taylor DM (2003). Antipsychotics and QT prolongation. Acta Psychiatr Scand 107: 85-95.
31. Taylor DM, Young CL, Mace S, Patel MX (2004). Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 65: 1076-1083.